In the Mix: 36 More Articles — June 15, 2026

Ukraine Turns to Medical Cannabis to Support Veterans – The Fresh Toast

Ukraine has initiated a medical cannabis program targeting veterans, particularly those with combat-related trauma and chronic pain conditions. While cannabis shows potential therapeutic applications, the evidence base remains limited regarding optimal dosing regimens, long-term safety profiles, and comparative efficacy against established treatments for conditions like PTSD and neuropathic pain. The program reflects growing international interest in cannabinoid-based therapeutics for trauma-related disorders, though rigorous controlled trials are still lacking in this population. Current research suggests cannabinoids may modulate pain and anxiety pathways, but definitive clinical guidance for veterans’ populations has not yet been established. Despite cannabis’s controversial regulatory status in many jurisdictions, this initiative may provide valuable real-world data on dosing, adverse effects, and outcomes in a specific patient cohort with high clinical need. Clinicians should monitor emerging evidence from such programs as they may inform future evidence-based guidelines for cannabinoid use in trauma and chronic pain management.

Cross-Disorder Pruning-Plasticity-Aging Architecture in Substance Use Disorders and Anxiety

# Clinical Summary This study employs transcriptome-wide association study (TWAS) methodology to identify shared genetic architecture across cannabis use disorder, anxiety disorders, and aging-related pathways. The research suggests that alterations in synaptic pruning and plasticity mechanisms may represent a common biological pathway underlying both substance use disorders and anxiety, potentially explaining their frequent comorbidity. The findings indicate that gene sets involved in neuronal pruning, synaptic plasticity, and aging processes show cross-disorder associations that could inform understanding of why cannabis use disorder and anxiety often co-occur. These results may have implications for understanding the neurobiological mechanisms linking these conditions and could eventually inform more targeted treatment approaches. Despite representing primarily mechanistic rather than immediately actionable clinical evidence, this work merits attention for clinicians managing patients with comorbid cannabis use disorder and anxiety, as it provides biological context for what remains a clinically challenging population.

Doctors slam medicinal cannabis driving policy | 7NEWS – YouTube

# Clinical Summary A group of trauma physicians in Australia have publicly opposed a proposed state policy that would permit patients using medicinal cannabis to operate motor vehicles. The doctors’ criticism centers on concerns that cannabis impairs driving ability and increases accident risk, regardless of therapeutic indication. The policy under consideration by the Minns Government appears to lack robust safety assessments regarding cognitive and motor function in medicated patients. Trauma specialists, who regularly treat motor vehicle accident victims, are positioned to observe firsthand the consequences of impaired driving. Medical licensing bodies may need to establish clear guidelines on cannabis use and driving fitness similar to those for other psychoactive medications. This article merits review by clinicians involved in cannabis prescribing and impairment assessment, as it highlights potential regulatory gaps between therapeutic approval and real-world safety governance.

Splash Beverage Group Invests $217,479 in Avicanna via Private Placement to Advance …

Splash Beverage Group has invested $217,479 in Avicanna through a private placement agreement as part of a strategic pivot toward cannabinoid-focused health and wellness products. This investment reflects continued commercial interest in cannabis-infused beverages as a delivery mechanism for cannabinoids, though clinical efficacy data for beverage formulations remain limited. The transaction underscores ongoing industry consolidation and capital reallocation toward cannabis products in mainstream consumer channels. Private placement investments in cannabis companies are common but do not indicate regulatory approval or clinical validation of products. This development may be relevant for clinicians tracking market trends and the commercialization of cannabinoid products that patients may encounter, despite the absence of significant new clinical evidence.

Tilray Reports 73% Revenue Growth in International Cannabis Business | Intellectia.AI

Tilray reported $206.7 million in quarterly sales representing 73% revenue growth, with substantial contributions from its international cannabis business segment. The company’s financial performance reflects expanding market penetration across jurisdictions where cannabis has achieved regulatory approval for medical or recreational use. This growth trajectory suggests increasing clinical legitimacy and market accessibility for cannabis-derived products in international settings. However, the clinical summary lacks specific data on product types, therapeutic applications, or patient outcomes that would inform prescribing decisions. Revenue expansion alone does not establish efficacy or safety profiles for individual cannabis formulations or cannabinoid compounds. Clinicians may find value in monitoring industry consolidation patterns as they potentially correlate with standardization efforts that could improve product consistency and clinical reliability.

Fresh Connection Royal Gelato | 1g – Terpene Journey

This product contains raw cannabis precursors, primarily THCA, which converts to THC upon heating through decarboxylation. The conversion process does not occur at a 1:1 ratio, meaning the final THC content will be lower than the initial THCA concentration, typically yielding approximately 0.877 mg of THC per 1 mg of THCA due to the loss of a carboxyl group during decarboxylation. The product is non-intoxicating in its raw form, making it potentially suitable for patients seeking to avoid psychoactive effects until or unless heat is applied. Understanding the decarboxylation efficiency is clinically relevant for patients attempting precise dosing, as they cannot assume labeled THCA content will translate directly to bioavailable THC. The specific terpene profile mentioned may provide additional therapeutic effects beyond cannabinoids, though the summary provided does not detail which terpenes are

Splash Beverage advances cannabinoid strategy with Avicanna investment – TipRanks.com

Splash Beverage has invested in Avicanna, a cannabinoid biopharmaceutical company, as part of a strategic shift toward developing cannabinoid-based products across health, wellness, and pharmaceutical applications. This investment reflects growing commercial interest in translating cannabis compounds into regulated pharmaceutical formulations beyond traditional cannabis products. The partnership suggests industry movement toward standardized cannabinoid therapies with defined dosing and clinical validation. While the specific therapeutic targets and clinical development stage of Avicanna’s pipeline are not detailed in this announcement, such investments may accelerate research into cannabinoid mechanisms relevant to future medical applications. For clinicians, this represents the ongoing commercialization of cannabinoid research rather than new clinical evidence. Readers may still find value in tracking how beverage and consumer companies are reshaping cannabinoid development, as this market consolidation could influence product availability and formulation standards in clinical settings.

Foxborough Moves To Stop Home Delivery Of Cannabis | WBZ NewsRadio 1030 – iHeart

Foxborough, Massachusetts is implementing regulatory measures to restrict cannabis access within its municipality by prohibiting both retail dispensaries and home delivery services. This represents a local policy decision to limit cannabis distribution channels rather than a clinical or pharmacological development. The move reflects ongoing municipal variation in cannabis regulation across states where legalization has occurred, with some jurisdictions choosing to opt out of retail sales entirely. From a clinical perspective, this primarily affects patient access patterns and supply chain logistics rather than therapeutic outcomes or safety profiles. Healthcare providers should remain aware of such local restrictions as they may impact patient ability to obtain cannabis for medical purposes in specific regions. Despite limited direct clinical significance, this article illustrates the complex patchwork of cannabis regulations that clinicians should understand when counseling patients about legal access to cannabis-based treatments.

Trulieve Set to Become First Cannabis Company Listed on the NYSE – Tallahassee Reports

# Clinical Summary Trulieve Cannabis Corporation, the largest cannabis retailer in Florida and among the largest in the United States, is preparing to become the first cannabis company to achieve listing on the New York Stock Exchange. This represents a significant shift in cannabis industry legitimacy and market accessibility, as major equity exchanges have historically restricted cannabis company listings due to federal prohibition. NYSE listing would potentially increase institutional investment in cannabis companies and may signal evolving regulatory perspectives on the industry. The move reflects the cannabis market’s maturation in states where it has been legalized, though federal legal barriers remain. While this development has minimal direct clinical impact on cannabis therapeutics or patient outcomes, it merits attention as market consolidation and institutional investment patterns may influence research funding, product standardization, and regulatory evolution in ways that could eventually affect clinical cannabis research and therapeutic applications.

OBN agents seize 49,000 marijuana plants in black market bust – OKC Fox

Law enforcement agents conducted a raid on illegal marijuana cultivation operations, resulting in the seizure of 49,000 plants and the arrest of seven individuals. This large-scale black market operation highlights the ongoing presence of unlicensed cultivation despite legal cannabis markets in many jurisdictions. The seizure demonstrates that illegal growing operations continue to operate parallel to regulated cannabis markets, potentially supplying unregulated products that may lack quality testing and safety verification. Such illicit operations create public health concerns related to pesticide residues, microbial contamination, and unknown cannabinoid potency that consumers may be unaware of when purchasing from black market sources. While this enforcement action has limited direct clinical relevance, it may inform clinicians about the continued prevalence of unregulated cannabis use in their communities and the potential health implications of patients consuming untested products.

Youth ODs in northern Ont. on what he thought was cannabis – YouTube

A fatal overdose in Garden River First Nation involved a youth who consumed a substance believed to be cannabis but was likely an illicit product containing unknown adulterants or synthetic compounds. Police investigations into such cases highlight the ongoing contamination of illicit cannabis supplies with potent opioids, synthetic cannabinoids, and other dangerous substances that pose acute toxicity risks. This incident underscores the hazard differential between regulated cannabis products and illicit market alternatives, particularly regarding unpredictable potency and undisclosed adulterants that can precipitate overdose in naive users. Clinicians should remain alert to the possibility of non-cannabis toxic exposures when evaluating young patients presenting with acute toxidrome features following reported cannabis use. The case exemplifies how illicit drug supply contamination can result in fatal outcomes even among users with no prior overdose risk factors. While not a primary clinical evidence source, this incident serves as a reminder that real-world harms from contam

Antiguan-born Pastor and Barber Held After EC$357,000 Cannabis Bust at V.C. Bird Airport

Law enforcement at V.C. Bird Airport in Antigua and Barbuda seized approximately 60 pounds of cannabis valued at EC$357,000 from luggage belonging to an Antiguan-born U.S. resident who works as a pastor and barber. The individual is cooperating with local police authorities during their investigation into the attempted transportation of this substantial quantity of controlled substance. This seizure represents a significant drug interdiction effort at a major Caribbean transportation hub. The case highlights ongoing challenges with cannabis trafficking through regional airports despite increasing legalization in North American jurisdictions. While this incident has limited direct clinical relevance, it may merit attention for understanding how divergent cannabis legal frameworks between Caribbean nations and North American countries continue to drive trafficking patterns that complicate public health messaging and clinical practice.

40 Charges Filed After Metro East Crime Detail | RiverBender.com

This law enforcement report documents arrests made during a metro area crime detail operation, with cannabis and controlled substances seized during the enforcement action. The article provides limited clinical information and focuses primarily on arrest statistics and police activity rather than medical or public health outcomes. The specific quantities of substances seized (198.5 grams of controlled substances alongside cannabis) are noted but lack context regarding substance types or patient-related implications. This report has minimal direct clinical relevance for medical practitioners or researchers focused on cannabis pharmacology, therapeutic applications, or adverse health outcomes. The article may still warrant review for clinicians interested in regional drug enforcement patterns and their potential correlation with substance availability and public health trends in the metro east area.

Five arrested in McCalla drug raid with narcotics and firearm seized – WVTM

Law enforcement conducted a drug raid in McCalla that resulted in five arrests and seizure of multiple controlled substances including tramadol, marijuana, methamphetamine, clonazepam, and alprazolam, along with a firearm. The operation highlights the continued presence of polydrug use patterns involving opioids, benzodiazepines, stimulants, and cannabis in community settings. This case demonstrates the real-world complexity of substance abuse in populations where patients may present with multiple concurrent drug dependencies requiring comprehensive assessment and treatment planning. Clinicians should remain aware that patients reporting cannabis use may simultaneously be using other controlled substances, particularly benzodiazepines and opioids, which carry significant interaction risks and overdose potential. The seizure of both prescription medications (tramadol, clonazepam, alprazolam) and illicit drugs underscores the challenge of distinguishing between diverted pharmaceuticals and street drugs in emergency

Narcotics and Weapon Seizure in McCalla – Jefferson County Sheriff’s Office

This article reports a law enforcement seizure involving 4.2 grams of marijuana alongside methamphetamine and unidentified substances in McCalla, Alabama. The seizure included paraphernalia consistent with active drug use, specifically a glass pipe with burnt residue. The clinical relevance is limited as the article focuses on law enforcement activity rather than medical outcomes, pharmacology, or patient care implications. No information is provided regarding the individuals involved, their medical status, or any clinical consequences of the seizure. This report has minimal direct application to clinical cannabis medicine or substance use disorder management. Healthcare providers interested in understanding local drug seizure patterns and community substance use epidemiology may find the geographic and temporal context useful for contextualizing patient presentations in the region.

Cannabis found in student’s bag – Antigua Observer Newspaper

A secondary school student in Antigua was found to be in possession of cannabis after a parent’s search for a missing kitchen knife led to discovery of the substance in the student’s school bag. The incident highlights the ongoing challenge of substance use among adolescents in educational settings and the role parents and guardians play in identifying concerning behavior through direct intervention. The case underscores the importance of early detection and appropriate referral pathways for youth substance use, as adolescent cannabis exposure carries documented risks including potential impacts on cognitive development and educational outcomes. Schools and parents should maintain open communication and establish clear protocols for responding to substance discoveries that prioritize student health and appropriate intervention. While this report lacks specific clinical details about the student’s use patterns or any documented adverse effects, it may still be worth reading for administrators and educators seeking practical insights into family-based detection strategies and school-based response frameworks for adolescent cannabis possession.

"I never liked the smell" – Shaquille O’Neal explains why he never smokes marijuana and …

The NBA removed marijuana from its prohibited substances list in 2023 as part of a new collective bargaining agreement, reflecting broader shifts in cannabis policy within professional sports. Shaquille O’Neal, a prominent retired NBA player, has publicly stated he does not use marijuana and cited sensory aversion as his primary reason for non-use. This statement from a high-profile athlete may influence perceptions among younger populations regarding cannabis consumption patterns and personal choice. The article appears to focus on individual athlete preferences rather than clinical outcomes or medical evidence regarding cannabis use in sports contexts. While this report lacks direct clinical relevance to medical practice, it may be useful for understanding how elite athletes and public figures are shaping cannabis-related attitudes and behaviors in their audiences.

Soothing Lemon Lime Chews (Formerly Lemon Lime Terpene Infused Chews) | Key Missouri (Rolla)

This product description provides minimal clinical information for evidence-based evaluation. The formulation contains 25 mg of an unspecified cannabinoid labeled “Pain” with added lemon-lime terpenes, though the active ingredient, cannabinoid profile, and THC to CBD ratio are not disclosed. No pharmacokinetic data, dosing guidance, onset time, duration of effect, or clinical evidence supporting efficacy for pain management are presented. The terpene profile may theoretically contribute to analgesic or anti-inflammatory effects through entourage mechanisms, but this remains speculative without standardized composition data. Despite limited clinical utility, the product information highlights the ongoing need for standardized labeling requirements and transparent cannabinoid quantification in the cannabis industry to enable proper clinical assessment and patient counseling.

Father’s Day Gifts for Every Kind of Dad, From THC Drinks to Premium Tequila – Parade

This article presents a consumer gift guide featuring various alcohol products and THC-infused beverages marketed for Father’s Day. The piece highlights THC drinks alongside traditional alcoholic options such as premium tequila, canned cocktails, and rosé wines without addressing potential drug interactions, contraindications, or safe use parameters for cannabis consumers. No clinical data, dosing information, or risk stratification is provided to guide patient counseling or medical decision-making regarding these products. The article lacks any discussion of the pharmacological effects of combining THC with alcohol or considerations for patients with relevant comorbidities. While this article has limited direct clinical utility, it may warrant brief review to understand the marketing and accessibility of cannabis products to the general public, which could inform discussions with patients about consumption patterns and product types encountered in their communities.

How to Buy Weed in Mykonos: Greek Island Cannabis & What Party Tourists Should Know …

Greece has established a regulatory framework for medical cannabis through Law 4523/2018, which amended the previous Law 4139/2013. Medical cannabis products in Greece must undergo evaluation and approval through the official medicine regulatory system before distribution. The article addresses recreational cannabis access on Greek islands, which remains outside legal medical frameworks and reflects the distinction between regulated therapeutic use and uncontrolled recreational markets. Tourists seeking cannabis in destinations like Mykonos should understand the legal distinction between Greece’s medical cannabis program and the legal status of non-medical use. The regulatory pathway for medical cannabis in Greece mirrors other European models with centralized approval processes for final pharmaceutical products. Despite its focus on tourist-oriented information rather than clinical guidance, the article may interest clinicians working with patients traveling internationally who use medical cannabis products.

"Zootopia Strain Review: A Wildly Good Cannabis Experience" – Balanced Potency … – Ac Pisa 1909

The article reviews the Zootopia cannabis strain, emphasizing its balanced potency and terpene profile as key characteristics. Terpenes, the aromatic volatile compounds in cannabis, are highlighted as significant contributors to the strain’s effects and sensory experience. The review suggests Zootopia offers a sophisticated combination of these aromatic compounds, though specific terpene concentrations and cannabinoid ratios are not detailed in the summary provided. The strain appears marketed toward consumers seeking balanced effects rather than high-THC potency. This consumer-focused review lacks the controlled clinical data, adverse effect documentation, and pharmacokinetic information needed for direct clinical application. Nevertheless, strain reviews reflecting consumer preferences and terpene combinations may provide indirect insights into how patients self-select cannabis products for symptom management.